Our first AI discovered candidate enters laboratory validation
The first candidate designed end to end by Syngenis One has entered laboratory validation, completing the full discovery to laboratory workflow for the first time.
Our first AI discovered candidate was designed by Syngenis One and has entered laboratory validation, the first to complete the full discovery to laboratory workflow. It is a milestone for our platform and for the integrated model that sits behind it.
Syngenis One identifies targets, designs RNA and DNA candidates, screens for off target effects and orders synthesis, all in one guided workflow. Carrying a candidate from that workflow into validated laboratory material, without leaving the country, is exactly the capability Syngenis was built to provide.
Research grade manufacturing is operational and generating revenue today, and we are building GMP grade capability. We work alongside leading Australian and international universities, research institutes and biotechnology companies, and we will share further milestones here as programs progress.
Bring your program to Syngenis
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.